LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.25 5.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.18

Max

1.28

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+335.71% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	3.5M 129M
Eelmine avamishind	-4.68
Eelmine sulgemishind	1.25

Uudiste sentiment

By Acuity

50%

155 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. veebr 2026, 16:32 UTC

Tulu

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13. veebr 2026, 21:57 UTC

Tulu

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. veebr 2026, 21:20 UTC

Tulu

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. veebr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. veebr 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. veebr 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. veebr 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. veebr 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. veebr 2026, 19:51 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:29 UTC

Tulu

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. veebr 2026, 18:18 UTC

Omandamised, ülevõtmised, äriostud

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. veebr 2026, 17:52 UTC

Tulu

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. veebr 2026, 17:16 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 17:10 UTC

Omandamised, ülevõtmised, äriostud

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. veebr 2026, 16:59 UTC

Tulu

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. veebr 2026, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. veebr 2026, 16:11 UTC

Tulu

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. veebr 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. veebr 2026, 15:54 UTC

Tulu

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. veebr 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. veebr 2026, 15:01 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. veebr 2026, 15:00 UTC

Tulu

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. veebr 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. veebr 2026, 14:44 UTC

Tulu

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. veebr 2026, 14:22 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

13. veebr 2026, 14:21 UTC

Market Talk

Tulu

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13. veebr 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

335.71% tõus

12 kuu keskmine prognoos

Keskmine 4.88 USD 335.71%

Kõrge 8 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

155 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.